

March 20, 2020

The World Health Organization (WHO) has declared the COVID-19 (coronavirus) outbreak a global pandemic. We extend our heartfelt sympathies to everyone who has lost loved ones, to patients and healthcare professionals battling this devastating outbreak.

With multiple countries implementing measures to slow the spread of the virus, based on the current situation, we wanted to provide an update to the community that Hemlibra supply continues to be stable for the foreseeable future.

We understand the importance of Hemlibra for people with hemophilia A and are committed to ensuring adequate supply. We are actively assessing and managing the situation on a daily basis, and have not identified any critical components that would impact our ability to supply Hemlibra in the future, based on current demand forecasts. Our global manufacturing network has robust plans for dealing with the impact of potential health and other global crises. All manufacturing sites have site-specific plans in place with the goal of avoiding interruptions of product manufacturing, packaging or delivery for all of Genentech's medicines, including Hemlibra. We are also engaged with all of our key suppliers to mitigate any potential impact to our supply chain.

We are continually taking proactive measures in collaboration with our logistics service providers to ensure the delivery of products to and from affected countries and regions remains stable. Should we become aware of any change to the supply or availability of Hemlibra at any point, we will inform the hemophilia community immediately.

We understand those living with hemophilia A and their loved ones may be facing a high level of uncertainty. Although our team will not be attending local chapter events or inperson meetings for the time being, we will continue to support the community as a dedicated educational and informational resource and look forward to continuing our community work in the weeks and months to come. If you have any questions, please reach out to your local CE.

We recognize that the public and private sectors across the globe need to work together to help effectively manage this developing situation. For further details on Genentech's efforts related to COVID-19 please refer to our <u>statement</u> and <u>media releases</u> on gene.com.